Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Accuray Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Accuray şirketinin kazançları yıllık ortalama -27.4% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 11.5% oranında artan oldu. Gelirler yıllık ortalama 2.7% oranında artan oldu.

Anahtar bilgiler

-27.4%

Kazanç büyüme oranı

-25.3%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	8.9%
Gelir büyüme oranı	2.7%
Özkaynak getirisi	-34.5%
Net Marj	-3.5%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Aug 18

Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues

Aug 13

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

May 21

Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

May 04

Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

Aug 17

These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

Apr 13

The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Mar 14

Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

Dec 01

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Oct 27

Accuray launches CyberKnife platform in Africa for cancer patients

Sep 30

Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M

Aug 10

Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden

Jul 08

Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger

Jun 15

Accuray: Nothing Special

May 31

Accuray Once Again Hits The Reset Button On Its Progress

Feb 09

A Look At The Fair Value Of Accuray Incorporated (NASDAQ:ARAY)

Jan 28

Gelir ve Gider Dağılımı

Accuray nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:ARAY Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	447	-16	92	48
31 Mar 24	431	-21	91	53
31 Dec 23	447	-15	91	58
30 Sep 23	455	-7	92	57
30 Jun 23	448	-9	92	57
31 Mar 23	439	-10	97	58
31 Dec 22	417	-12	96	57
30 Sep 22	419	-10	94	57
30 Jun 22	430	-5	94	58
31 Mar 22	431	-13	92	59
31 Dec 21	437	-12	93	58
30 Sep 21	418	-8	89	55
30 Jun 21	396	-6	85	53
31 Mar 21	380	5	83	50
31 Dec 20	377	8	81	47
30 Sep 20	379	14	81	49
30 Jun 20	383	4	87	50
31 Mar 20	405	3	92	54
31 Dec 19	409	-1	97	55
30 Sep 19	413	-17	101	56
30 Jun 19	419	-16	106	56
31 Mar 19	415	-16	109	55
31 Dec 18	412	-24	110	56
30 Sep 18	410	-24	111	57
30 Jun 18	405	-24	108	57
31 Mar 18	403	-28	105	56
31 Dec 17	401	-24	103	55
30 Sep 17	388	-29	102	52
30 Jun 17	383	-30	101	50
31 Mar 17	366	-32	100	51
31 Dec 16	374	-26	102	52
30 Sep 16	396	-22	106	55
30 Jun 16	399	-26	107	57
31 Mar 16	406	-24	108	57
31 Dec 15	398	-28	106	57
30 Sep 15	387	-32	107	55
30 Jun 15	380	-40	109	56
31 Mar 15	380	-44	111	54
31 Dec 14	380	-46	113	55
30 Sep 14	375	-42	110	55
30 Jun 14	369	-35	107	54
31 Mar 14	352	-44	103	55
31 Dec 13	326	-71	101	57

Kaliteli Kazançlar: ARAY şu anda kârlı değil.

Büyüyen Kar Marjı: ARAY şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ARAY kârlı değildir ve zararlar son 5 yılda yılda 27.4% oranında artmıştır.

Büyüme Hızlandırma: ARAY 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ARAY kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 7.9% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: ARAY hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -34.48% ) sahiptir.

Accuray Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated to Report Q4, 2024 Results on Aug 14, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Accuray Incorporated to Report Q3, 2024 Results on May 01, 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Accuray Incorporated to Report Q2, 2024 Results on Jan 31, 2024

Recent updates

Accuray Incorporated announced delayed annual 10-K filing

Accuray Incorporated President Suzanne Winter to Take Temporary Medical Leave of Absence

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Forecast breakeven date pushed back to 2026

New major risk - Share price stability

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Provides Earnings Guidance for the Fiscal Year 2025

Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues

Accuray Incorporated to Report Q4, 2024 Results on Aug 14, 2024

Accuray Incorporated Announces Approval of the Accuray Precision Treatment Planning System by China's National Medical Products Administration

Forecast breakeven date pushed back to 2026

Independent Chairman of the Board recently bought US$156k worth of stock

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

Accuray Incorporated Announces Executive Changes, Effective May 17, 2024

Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

Price target decreased by 11% to US$7.75

Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?

Accuray Incorporated Provides Earnings Guidance for the Year 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 35% undervalued after recent price drop

Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024

Accuray Incorporated to Report Q3, 2024 Results on May 01, 2024

Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp

Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System

New minor risk - Shareholder dilution

Is Accuray (NASDAQ:ARAY) A Risky Investment?

Second quarter 2024 earnings: EPS misses analyst expectations

Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024

Accuray Incorporated to Report Q2, 2024 Results on Jan 31, 2024

President recently sold US$162k worth of stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

President recently sold US$99k worth of stock

Accuray Incorporated to Report Q1, 2024 Results on Nov 07, 2023

Accuray Announces Approval of the Tomo C Radiation Treatment Delivery System by China's National Medical Products Administration

Accuray Incorporated, Annual General Meeting, Nov 09, 2023

Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

Full year 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2025

Accuray Incorporated Provides Revenue Guidance for Fiscal Year 2024

Accuray Incorporated to Report Q4, 2023 Results on Aug 09, 2023

President recently sold US$65k worth of stock

Insider recently sold US$93k worth of stock

Accuray Incorporated Announces New Data Presented at the European Society for Radiotherapy and Oncology

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Accuray Incorporated Announces Data from Randomized, Multicenter Trial PACE-A

High number of new directors

Accuray Incorporated Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Announces the Appointment of Robert C. Kill to its Board of Directors

Accuray Incorporated to Report Q2, 2023 Results on Feb 01, 2023

Accuray Incorporated Announces First Patient Treatments in New Zealand with the CyberKnife(R) System

Accuray Incorporated Announces Intent to Resign from Position as Chief Accounting Officer and Principal Accounting Officer, Effective January 3, 2023

Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

First quarter 2023 earnings: EPS and revenues miss analyst expectations

President recently sold US$76k worth of stock

Accuray Incorporated Re-Affirms Guidance for Year 2023

Accuray Announces Tomo C Registration Submission to China's National Medical Products Administration

High number of new directors

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Japanese Ministry of Health, Labor and Welfare Approves Reimbursement for the Cyberknife(R) System for the Treatment of Trigeminal Neuralgia

Accuray Incorporated to Report Q1, 2023 Results on Nov 02, 2022

Accuray Incorporated Announces Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators

Accuray Incorporated, Annual General Meeting, Nov 10, 2022

Accuray launches CyberKnife platform in Africa for cancer patients

Richard R. Pettingill Not to Stand for Re-Election as Class I Director of Accuray Incorporated

Accuray Incorporated Appoints Seth Blacksburg as Chief Medical Officer

Full year 2022 earnings: EPS and revenues exceed analyst expectations